{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:46:41Z","timestamp":1789958801792,"version":"4.0.1"},"reference-count":39,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2012,5,28]],"date-time":"2012-05-28T00:00:00Z","timestamp":1338163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2012,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Imatinib has dramatically improved the clinical outcome in chronic myeloid leukemia, chronic phase (CMLcp), but a risk of resistance and serious disease progression still prevails. We have studied 45 newly diagnosed CMLcp patients initiated on imatinib, assessing treatment responses by interphase extral signal (ES)\u2010fluorescence in situ hybridization (FISH), quantitative real\u2010time (q\u2010RT) polymerase chain reaction (PCR), and chromosome banding analysis. In a landmark analysis, an early favorable response, defined as less than 10% BCR\u2010ABL\u2010positive cells by FISH after 3 months of treatment, was identified as a predictive marker of an improved long\u2010term clinical outcome. Of evaluable patients, 51% achieved this response. A large majority, 95% of such responders reached complete cytogenetic responses (CCyR) within 12 months and 100% event\u2010free survival (EFS) at 48 months, when compared with 67 and 65%, respectively, of patients with higher breakpoint cluster region \u2010 Abelson (BCR\u2010ABL) positivity at 3 months (<jats:italic>P<\/jats:italic> = 0.04; <jats:italic>P<\/jats:italic> = 0.006). No similar, significant correlations were noted between early disease assessments with PCR of BCR\u2010ABL mRNA transcripts or of cytogenetics versus a 12\u2010month CCyR or long\u2010term EFS. Our data, based on a limited patient cohort, indicate that (i) FISH can effectively be used in the early assessment of remaining Ph\u2010positive cells to identify patients at risk for a long\u2010term nonoptimal response to imatinib and that (ii) FISH may be more useful than PCR for this purpose. Am. J. Hematol., 2012. \u00a9 2012 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.23238","type":"journal-article","created":{"date-parts":[[2012,4,26]],"date-time":"2012-04-26T12:46:47Z","timestamp":1335444407000},"page":"760-765","source":"Crossref","is-referenced-by-count":18,"title":["Early landmark analysis of imatinib treatment in CML chronic phase: Less than 10% BCR\u2010ABL by FISH at 3 months associated with improved long\u2010term clinical outcome"],"prefix":"10.1002","volume":"87","author":[{"given":"Lotta","family":"Ohm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Arvidsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisela","family":"Barbany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif","family":"Stenke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,5,28]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"85","article-title":"Chromosome studies on normal and leukemic human leukocytes","volume":"25","author":"Nowell PC","year":"1960","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2406902"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.17.6649"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-131-3-199908030-00008"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergencyto.2003.08.018"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergencyto.2004.02.026"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-150680"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0596-561"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-06-161737"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.2373"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"e_1_2_5_15_2","first-page":"451","article-title":"Upfront imatinib therapy in CML patients with rapid switching to nilotinib for failure to achieve molecular targets or intolerance achieves high overall rates of molecular response and a low risk of progression\u2014An update of the TIDEL\u2010II trial","volume":"118","author":"Yeung DT","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_2_5_16_2","volume-title":"Guidelines for Cancer Cytogenetics","author":"Schaffer IG","year":"2005"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-005686"},{"key":"e_1_2_5_18_2","first-page":"1471","article-title":"The impact of RNA stabilization on minimal residual disease assessment in chronic myeloid leukemia","volume":"90","author":"Thorn I","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403136"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403135"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0779"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1532\/IJH97.04095"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.38"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-273979"},{"key":"e_1_2_5_25_2","first-page":"669","article-title":"Molecular response <1% BCR\u2010ABL IS at 12 months is associated with improved overall and progression\u2010free survival. The randomized German CML\u2010Study IV","volume":"116","author":"Muller MC","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-302323"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403077"},{"key":"e_1_2_5_28_2","first-page":"861","article-title":"Philadelphia chromosome\u2010positive myeloid cells in the peripheral blood of chronic myelogenous leukemia patients: Comparison with the frequency detected in cycling cells of the bone marrow","volume":"4","author":"Seong D","year":"1998","journal-title":"Clin Cancer Res"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-4608(02)00558-7"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25678"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190600783551"},{"key":"e_1_2_5_32_2","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1200\/JCO.2000.18.7.1533","article-title":"Fluorescence in situ hybridization on peripheral\u2010blood specimens is a reliable method to evaluate cytogenetic response in chronic myeloid leukemia","volume":"18","author":"Le Gouill S","year":"2000","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_33_2","first-page":"209","article-title":"Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: Interim results from the TIDEL\u2010II Trial","volume":"116","author":"Yeung DT","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.7963"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04899.x"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2208"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1159\/000046636"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.3109\/02841861003660031"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergencyto.2010.02.003"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-0092"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23238","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.23238","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T23:43:20Z","timestamp":1697499800000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.23238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,28]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["10.1002\/ajh.23238"],"URL":"https:\/\/doi.org\/10.1002\/ajh.23238","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,28]]}}}